The BPC-157 / TB-500 blend is one vial of the two peptides at a 1:1 ratio, sold as 5/5 or 10/10 mg.
A fixed-ratio blend requires component-aware arithmetic. Vial composition is kept separate from target amounts so component strengths are never presented as dose suggestions.
Choose the exact vial variant. The Advanced Blend workspace prefills each component and calculates every component concentration from one shared prepared volume.
Each listed number identifies how much of one component is present in the full vial. It does not establish how much of the blend to draw or how often.
Reported protocols describe how sources reconstitute and draw this vial as a whole, each tied to where it was said.
Each peptide's own page reports what studies and guides describe for it alone; the leading rows are repeated below.
The ratio is fixed by the vial, so a draw sized for one component sets the amount of all the others at the same time.
BPC-157 / TB-500 Blend is 2 peptides in one vial. Each profile below is PubChem's record for that peptide, read from its own library page; the vial amount is what the label states for this blend, not an amount per draw.
BPC-1575 mg in the 5 / 5 mg vial; 10 mg in the 10 / 10 mg vial
TB-500 / TB-45 mg in the 5 / 5 mg vial; 10 mg in the 10 / 10 mg vial
What published studies and recent community write-ups report about amounts, timing and course length. 1 clinical, 1 preclinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical1 row | |||||
| Clinical: intra-articular BPC 157 with TB4, retrospective chart review (combination subset)4 of 16 surveyed knee-pain patients at a Florida clinic who received BPC 157 together with TB4; the other 12 received BPC 157 alone | 2 peptide injections (BPC 157 and TB4) into the knee; the amounts given to the combination group are not stated in the abstract | Single procedure | Intra-articular | One procedure, with phone follow-up 6-12 months laterNot applicable | Alternative Therapies in Health and Medicine (PubMed)2021 |
| 3 of the 4 combination patients reported significant improvement and 1 reported none, against 11 of 12 for BPC 157 alone. There was no control group, no standardized outcome measure and no blinding, and the TB4 was a compounded thymosin beta-4 rather than a labelled TB-500 fragment, so this records that the pairing has been used in a clinic, not evidence that it works. | |||||
| Preclinical1 row | |||||
| Preclinical: rat Achilles tendon repair, both peptides together32 male Sprague-Dawley rats after Achilles tendon transection and repair, 8 per group (vehicle, BPC-157, TB-500, both) | BPC-157 10 mcg/kg/day plus TB-500 60 mcg/kg/day | Once daily | Intraperitoneal injection | 30 days after surgery, reported as four weeksNot applicable | Joint Diseases and Related Surgery2026 |
| The only study to give the two peptides together. TB-500 alone produced the one statistically significant gain in load to failure and the lowest Bonar histology score; the combination group improved on the Movin score but did not differ from either single agent on any measure, and the authors suggest the peptides converge on shared downstream pathways. Four tendons per group went to histology, each compound was tested at a single dose, and the TB-500 was described as synthetic thymosin beta-4 bought from a research-chemical supplier, so this is an exploratory result rather than a verdict on the stack. | |||||
| Community-reported3 rows | |||||
| Community reference: 5/5 mg vial in 2 mL, 5 days on and 2 off | 10 units (0.1 mL) of a 5 mg/mL solution, giving 250 mcg of each peptide; 20 units gives 500 mcg of each | Once daily for 5 days, then 2 days off | Subcutaneous, abdomen; evening, at least 2 hours after the last meal | 20 draws per cycle (about a month); up to 3 consecutive cycles2 days off each week; a 2 month pause after 3 cycles | Community resource2026 |
| A vendor's measurement page for the 10 mg (5 + 5) vial: 2 mL of bacteriostatic water gives 5 mg/mL in total (2.5 mg/mL of each), so 1 unit on a U-100 syringe is about 25 mcg of each peptide, and at the 10-unit example one vial lasts exactly one 20-draw cycle. It gives 3-4 weeks refrigerated as the in-use window and says the same cycle pattern applies to the 20 mg (10 + 10) vial with the unit math halved. This is a vendor claim that describes itself as measurement math, not dosing guidance. | |||||
| Community guide: 500 mcg-1 mg of blend once daily | 500 mcg-1 mg of blend per draw (250-500 mcg of each peptide), 10-20 units of a 5 mg/mL solution | Once daily | Subcutaneous | 4-8 weeks (standard); 2-4 weeks at 1 mg (intensive)Not described | Community resource2025 |
| Describes the 10 mg (5 + 5) vial made up with 2 mL, giving 2.5 mg/mL of each peptide and 25 mcg of each per unit. Its standard protocol is 500 mcg-1 mg of blend once daily for 4-8 weeks and its intensive one is 1 mg once daily for 2-4 weeks; a 500 mcg daily draw empties the vial in 20 days. The page states that these figures are research-protocol convention rather than a dose-finding study, lists storage as 4 weeks refrigerated after mixing, and flags both components on the 2026 WADA list (BPC-157 under S0, TB-500 under S2.3). | |||||
| Community unit math: 10/10 mg vial | 1 mg of blend (500 mcg of each peptide) is 10 units of a 20 mg vial made up with 2 mL (10 mg/mL), or 15 units with 3 mL | Per draw; no schedule given | Subcutaneous | Not describedNot described | Community resource2026 |
| A calculator site's guide to the arithmetic of blend vials: total milligrams divided by water volume gives the concentration, and a 1 mg total-blend draw from a 10/10 vial in 2 mL is 10 units, against 20 units from a 5/5 vial in the same volume. It stresses that the ratio is fixed at the factory, that the syringe units only ever track the total concentration, and that there is no established human dose for either peptide or for the blend. Updated September 2026. | |||||
The vendor reference adds 2 mL of bacteriostatic water to the 10 mg (5 + 5) vial for 5 mg/mL, then draws 10 units (250 mcg of each peptide) once daily in the evening, 5 days on and 2 off, injected subcutaneously in the abdomen.
At 10 units a day the 20 draws of a 5-on/2-off month use the whole 10 mg vial, which is also about the end of the 3-4 week refrigerated in-use window the same page gives for the mixed solution.
Community guides place the standard course at 4-8 weeks of 500 mcg-1 mg of blend once daily; the vendor reference allows up to 3 consecutive monthly cycles and then a 2 month pause. No source gives a reason for these lengths beyond convention.
The one study of the pair gave rats 10 mcg/kg BPC-157 and 60 mcg/kg TB-500 by intraperitoneal injection every day for 30 days after tendon repair, with no breaks, and found no advantage over either peptide alone at the four-week endpoint.
Plus 5 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
What sources report for each peptide on its own. In BPC-157 / TB-500 Blend the vial ratio fixes the proportions, so one draw delivers every component at once and none can be raised without the others. The first rows from each component's table are shown here; its page carries the rest, each linked to its source. Descriptions of what others report, not instructions.
These fields come from the existing picker, blend catalog and observed presentation data. They are identity and availability context, not evidence of effectiveness.
The BPC-157 / TB-500 blend is one vial of the two peptides at a 1:1 ratio, sold as 5/5 or 10/10 mg. The vendor sells the 10/10 vial as Wolverine, and the pair is the most common repair stack online, marketed for tendon, ligament, muscle and joint recovery on the strength of each component's rodent literature. One animal study has tested the combination, a 2026 rat Achilles tendon trial in which the pair did no better than either peptide alone, and the only human report is a four-patient subset of an uncontrolled knee injection chart review, so the evidence for the stack lives on the component pages.
Fixed-ratio blend reference
Kept separate from single-peptide evidence and terminology.
Structured review queued
No evidence level is assigned until references and study models are reviewed.
Advanced Blend workspace
Calculator access performs arithmetic; it does not establish an amount or protocol.
No reviewed observation on file
The vial label remains the authoritative source for any calculation.
Each number is the vial amount for that component. It is not a per-draw amount.
5 curated references, each with its journal, year and study model, plus 5 community resources reported but not linked.